Rilzabrutinib for blood disorder shows promise in phase 1–2 clinical trial

In people with immune thrombocytopenia (ITP), the body produces destructive antibodies against platelets in the blood, which increases the risk of bruising, bleeding, hospitalization, death, fatigue, and an impaired quality of life. A drug called rilzabrutinib has generated promising safety and efficacy results in a recent international multi-center phase 1–2 ITP trial led by investigators at Massachusetts General Hospital (MGH).  The findings, which are published in the New England Journal of Medicine, pave the way for more advanced clinical trials.

source https://medicalxpress.com/news/2022-04-rilzabrutinib-blood-disorder-phase-clinical.html